Cetuximab and chemoradiation for rectal cancer--is the water getting muddy? (Q37697800)

22 August 2017

1 reference

title

Cetuximab and chemoradiation for rectal cancer--is the water getting muddy? (English)

1 reference

22 August 2017

0 references

1 reference

Rob Glynne-Jones

1

1 reference

22 August 2017

Suzy Mawdsley

series ordinal

2

1 reference

22 August 2017

Mark Harrison

series ordinal

3

1 reference

22 August 2017

publication date

1 April 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

49

1 reference

22 August 2017

issue

3

1 reference

22 August 2017

page(s)

278-286

1 reference

Preoperative versus postoperative chemoradiotherapy for rectal cancer

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109/02841860903536010

Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/02841860903536010

Chemotherapy with preoperative radiotherapy in rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/02841860903536010

Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results--EORTC 22921.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/02841860903536010

Pathological complete response following pre-operative chemoradiotherapy in rectal cancer: analysis of phase II/III trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/02841860903536010

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/02841860903536010

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/02841860903536010

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/02841860903536010

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/02841860903536010

EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/02841860903536010

The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/02841860903536010

Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/02841860903536010

mRNA expression of platelet-derived growth factor receptor-beta and C-KIT: correlation with pathologic response to cetuximab-based chemoradiotherapy in patients with rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/02841860903536010

Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/02841860903536010

Infusional 5-fluorouracil and ZD1839 (Gefitinib-Iressa) in combination with preoperative radiotherapy in patients with locally advanced rectal cancer: a phase I and II Trial (1839IL/0092).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/02841860903536010

Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/02841860903536010

A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/02841860903536010

Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/02841860903536010

The absence of an adverse effect of prolongation of radiation treatment of primary rectal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/02841860903536010

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/02841860903536010

Experiences from treatment-predictive KRAS testing; high mutation frequency in rectal cancers from females and concurrent mutations in the same tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/02841860903536010

Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/02841860903536010

Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/02841860903536010

The mechanism of action of radiosensitization of conventional chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/02841860903536010

Apoptosis as a cellular predictor for histopathologic response to neoadjuvant radiochemotherapy in patients with rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/02841860903536010

Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/02841860903536010

Antimetabolite radiosensitizers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/02841860903536010

Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/02841860903536010

Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/02841860903536010

Phase I-II trial of concurrent capecitabine and oxaliplatin with preoperative intensity-modulated radiotherapy in patients with locally advanced rectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/02841860903536010

Phase II study of weekly intravenous oxaliplatin combined with oral daily capecitabine and radiotherapy with biologic correlates in neoadjuvant treatment of rectal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/02841860903536010

Preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal cancer. A phase I-II multicenter study of the Dutch Colorectal Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/02841860903536010

Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/02841860903536010

Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/02841860903536010

Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/02841860903536010

Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/02841860903536010

Concurrent chemoradiation with capecitabine and weekly irinotecan as preoperative treatment for rectal cancer: results from a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/02841860903536010

Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/02841860903536010

Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/02841860903536010

Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109/02841860903536010

10.3109/02841860903536010

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference